Phaseline

Companies › Basilea Pharmaceutica

Basilea Pharmaceutica: clinical trials, targets and expected readouts

5 active drug programs in 8 registered trials: 6 Phase 1, 2 Phase 3; Other, Genitourinary, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
fosmanogepix
GPI-anchored wall transfer protein 1 inhibitor
IPCS1, HMG1, FKS1Phase 3Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on DialysisMar 2027
Ceftibuten
Bacterial penicillin-binding protein inhibitor
FTSZPhase 1Healthy VolunteerDec 2026
Ceftibuten-ledaborbactam etzadroxil
Beta-lactam antibiotic combined with beta-lactamase inhibitor
FTSZPhase 1Healthy VolunteerDec 2026
Ledaborbactam etzadroxil
Beta-lactamase inhibitor
FTSZPhase 1Healthy VolunteerDec 2026
BAL2420
Antibacterial agent
–Phase 1HealthyJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06733675Ceftibuten-ledaborbactam etzadroxilPhase 1Healthy VolunteerOtherDec 2026
NCT06733675Ledaborbactam etzadroxilPhase 1Healthy VolunteerOtherDec 2026
NCT06733675CeftibutenPhase 1Healthy VolunteerOtherDec 2026
NCT07881224fosmanogepixPhase 1Healthy Adult ParticipantsOtherMar 2027
NCT07500181BAL2420Phase 1HealthyOtherJun 2027
NCT07916181fosmanogepixPhase 1End Stage Renal Disease on DialysisGenitourinaryNov 2027
NCT05421858fosmanogepixPhase 3CandidemiaInfectious diseaseJan 2028
NCT06925321fosmanogepixPhase 3Invasive Mold InfectionsInfectious diseaseFeb 2028

Targets

FTSZ (3) IPCS1 (1) HMG1 (1) FKS1 (1)

Companies with the same targets

Qilu Pharmaceutical Mundipharma Research

Companies built like this

Shanghai Ark Biopharmaceutical Shanghai Argo Biopharmaceutical Tortugas Neuroscience Daewoong Pharmaceutical Sirnaomics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.